多靶点粪便DNA检测预防结肠癌:大型整合医疗系统中的结局
在包含15家医院和150家门诊的大型整合医疗系统中,2017至2018年共完成6835例多靶点粪便DNA(MT-sDNA)检测。1242例(18%)阳性,其中905例(73%)接受了结肠镜检查;557例(8%)检出腺瘤或癌,226例(18%)阳性者检出进展期腺瘤或癌;阳性后结肠镜不依从率为21%,检出1例进展期腺瘤或癌的成本为38849美元。
要点
- MT-sDNA阳性者中仅18%检出进展期腺瘤或癌,腺瘤检出率低。
- 阳性后结肠镜不依从率高达21%,是筛查策略实施的显著问题。
- 检出1例进展期腺瘤或癌的成本为38849美元。
核心结论
- MT-sDNA筛查策略的腺瘤检出率低,许多阳性检测在结肠镜检查中无显著发现。
- 阳性后未行结肠镜随访是显著问题,采用该筛查策略时需考虑。
研究设计与样本
- 队列研究,在包含15家医院和150家门诊的大型整合医疗系统中进行,使用电子数据采集结合人工病历回顾确认MT-sDNA结果并监测后续结肠镜结局。
- 2017至2018年1年间共完成6835例MT-sDNA检测。
主要发现
- 1242例(18%)检测阳性,其中1109例(89%)被转诊结肠镜,905例(73%)实际接受结肠镜。
- 阳性患者中11例(<1%)检出结直肠癌,215例(17%)检出进展期腺瘤,110例(9%)检出锯齿状腺瘤,546例(60%)检出腺瘤。
- 6835例检测者中557例(8%)检出腺瘤或癌;1242例阳性者中226例(18%)检出进展期腺瘤或癌。
- 阳性后结肠镜不依从率为21%,检出1例进展期腺瘤或癌的成本为38849美元。
临床怎么用
- 采用MT-sDNA筛查时需关注阳性后结肠镜随访的依从性,不依从率高达21%。
- MT-sDNA阳性者中仅18%检出进展期腺瘤或癌,需权衡检测成本与获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Multitarget stool DNA (MT-sDNA) testing is used in primary care as a screening test for colon cancer. Test effectiveness and patient compliance were examined in clinical practice. METHODS: We assessed outcomes of MT-sDNA testing in a cohort study conducted in a large integrated healthcare system comprising 15 hospitals and 150 outpatient clinics using advanced electronic data capture (Clarity2 [Epic, Verona, Wisc, USA] and REDCap [Encinitas, Calif, USA]) followed by manual chart review to confirm MT-sDNA test results and to monitor the outcomes of subsequent colonoscopy. RESULTS: A total of 6835 MT-sDNA tests were performed over 1 year between 2017 and 2018. Of 1242 patients (18%) who tested positive, 1109 (89%) were referred for colonoscopy, and 905 of them (73%) underwent colonoscopy. Eleven patients (<1%) with a positive test had colorectal cancer, 215 (17%) had advanced adenomas, 110 (9%) had serrated adenomas, and 546 (60%) patients had an adenoma. Of the 6835 patients tested, adenoma or cancer was found in 557 patients (8%). An advanced adenoma or cancer was found in 226 of 1242 patients with a positive test (18%). Nonadherence with colonoscopy after a positive test was high (21%), and the cost to detect 1 advanced adenoma or cancer was $38,849. CONCLUSIONS: The frequency of adenoma detection by an MT-sDNA screening strategy is low, and many positive tests are not associated with significant findings at colonoscopy. Failure to follow a positive test with colonoscopy is a significant problem that needs to be considered when this screening strategy is adopted.
引用
- Vakil N, Ciezki K, Huq N, et al. Multitarget stool DNA testing for the prevention of colon cancer: outcomes in a large integrated healthcare system. Gastrointest Endosc. 2020. PMID: 31904379. doi:10.1016/j.gie.2019.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。